IP Verse

Methods For Dose Initiation Of Aripiprazole Treatments

Patent No. EP4125903 (titled "Methods For Dose Initiation Of Aripiprazole Treatments") was filed by Otsuka Pharmaceutical on Apr 1, 2021. The application was issued on Oct 9, 2024.

Patent Summary

A two-injection initiation regimen for aripiprazole long-acting injectable (Ability Maintena) comprising two separate 300-400 mg intramuscular injections at different sites (gluteal and/or deltoid) on the first day of treatment, supplemented with a single oral dose of 2-30 mg aripiprazole, provides an alternative to the traditional 14-day oral overlap initiation regimen for patients with schizophrenia or bipolar I disorder.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJul 9, 2025RUSSELL
ZENTIVAJul 9, 2025GREINER
RUMIJul 8, 2025TER MEER STEINMEISTER & PARTNER
SANDOZJul 4, 2025MAIWALD
DR SCHONJul 1, 2025DR SCHON
MAIWALDJul 1, 2025MAIWALD
STADA ARZNEIMITTELJul 1, 2025HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4125903

OTSUKA PHARMACEUTICAL
Application Number
EP21720012A
Filing Date
Apr 1, 2021
Status
Granted And Under Opposition
Sep 6, 2024
Publication Date
Oct 9, 2024
External Links
Slate, Register , Google Patents